Free Trial
NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.16
$2.16
50-Day Range
$2.13
$2.16
52-Week Range
$0.75
$3.93
Volume
400 shs
Average Volume
359,530 shs
Market Capitalization
$133.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRDS stock logo

About Pardes Biosciences Stock (NASDAQ:PRDS)

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

PRDS Stock News Headlines

Pardes Biosciences Announces Closing of Tender Offer
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Pardes Biosciences Seeking Strategic Alternatives
Pardes Biosciences (PRDS) Receives a Hold from SVB Securities
See More Headlines
Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PRDS
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-96,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.51 per share

Miscellaneous

Free Float
36,711,000
Market Cap
$133.95 million
Optionable
Not Optionable
Beta
0.42
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Thomas G. Wiggans (Age 71)
    CEO & Chairman
    Comp: $859.4k
  • Dr. Uri A. Lopatin M.D. (Age 51)
    Founder & Director
    Comp: $786.96k
  • Ms. Heidi Henson CPA (Age 57)
    Chief Financial Officer
    Comp: $564.6k
  • Ms. Elizabeth Haber Lacy J.D. (Age 56)
    Gen. Counsel & Corp. Sec.

This page (NASDAQ:PRDS) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners